These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33017591)

  • 21. The Diagnostic Utility of IDH2 R172 Immunohistochemistry in Tall Cell Carcinoma With Reversed Polarity of the Breast.
    Sasaki E; Iwakoshi A; Satake T; Nakajima K; Kobayashi M; Ando Y; Koshikawa T; Masago K; Honma N; Nishimura R; Kato Y; Ichihara S
    Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):654-661. PubMed ID: 36222504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort.
    Lozada JR; Basili T; Pareja F; Alemar B; Paula ADC; Gularte-Merida R; Giri DD; Querzoli P; Cserni G; Rakha EA; Foschini MP; Reis-Filho JS; Brogi E; Weigelt B; Geyer FC
    Histopathology; 2018 Aug; 73(2):339-344. PubMed ID: 29603332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
    Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
    Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development.
    Lemonnier F; Cairns RA; Inoue S; Li WY; Dupuy A; Broutin S; Martin N; Fataccioli V; Pelletier R; Wakeham A; Snow BE; de Leval L; Pujals A; Haioun C; Paci A; Tobin ER; Narayanaswamy R; Yen K; Jin S; Gaulard P; Mak TW
    Proc Natl Acad Sci U S A; 2016 Dec; 113(52):15084-15089. PubMed ID: 27956631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132L and IDH2-R172M mutations.
    Ogasawara S; Kaneko MK; Tsujimoto Y; Liu X; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2013 Dec; 32(6):377-81. PubMed ID: 24328739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
    Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
    Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IDH2 R172 Mutations Across Poorly Differentiated Sinonasal Tract Malignancies: Forty Molecularly Homogenous and Histologically Variable Cases With Favorable Outcome.
    Glöss S; Jurmeister P; Thieme A; Schmid S; Cai WY; Serrette RN; Perner S; Ribbat-Idel J; Pagenstecher A; Bläker H; Keber U; Stadelmann C; Zechel S; Johann PD; Hasselblatt M; Paulus W; Thomas C; Dohmen H; Baumhoer D; Frank S; Agaimy A; Schüller U; Vasudevaraja V; Snuderl M; Liu CZ; Pfister DG; Jungbluth AA; Ghossein RA; Xu B; Capper D; Dogan S
    Am J Surg Pathol; 2021 Sep; 45(9):1190-1204. PubMed ID: 34265800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors.
    Schenkel LC; Mathew J; Hirte H; Provias J; Paré G; Chong M; Grafodatskaya D; McCready E
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36360312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues.
    Horbinski C; Kofler J; Kelly LM; Murdoch GH; Nikiforova MN
    J Neuropathol Exp Neurol; 2009 Dec; 68(12):1319-25. PubMed ID: 19915484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.
    Frenel JS; Leux C; Loussouarn D; Le Loupp AG; Leclair F; Aumont M; Mervoyer A; Martin S; Denis MG; Campone M
    J Neurooncol; 2013 Aug; 114(1):85-91. PubMed ID: 23681562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
    Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
    Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of TFH Markers and Detection of RHOA p.G17V and IDH2 p.R172K/S Mutations in Cutaneous Localizations of Angioimmunoblastic T-Cell Lymphomas.
    Leclaire Alirkilicarslan A; Dupuy A; Pujals A; Parrens M; Vergier B; Robson A; Delfau-Larue MH; Ingen-Housz-Oro S; Chosidow O; Haioun C; Beylot-Barry M; Merlio JP; Copie-Bergman C; Gaulard P; Ortonne N
    Am J Surg Pathol; 2017 Dec; 41(12):1581-1592. PubMed ID: 28945625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
    Kipp BR; Voss JS; Kerr SE; Barr Fritcher EG; Graham RP; Zhang L; Highsmith WE; Zhang J; Roberts LR; Gores GJ; Halling KC
    Hum Pathol; 2012 Oct; 43(10):1552-8. PubMed ID: 22503487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms.
    Kurt H; Bueso-Ramos CE; Khoury JD; Routbort MJ; Kanagal-Shamanna R; Patel UV; Jorgensen JL; Wang SA; Ravandi F; DiNardo C; Luthra R; Medeiros LJ; Patel KP
    Am J Surg Pathol; 2018 May; 42(5):569-577. PubMed ID: 29635257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation.
    Kunadt D; Stasik S; Metzeler KH; Röllig C; Schliemann C; Greif PA; Spiekermann K; Rothenberg-Thurley M; Krug U; Braess J; Krämer A; Hochhaus A; Scholl S; Hilgendorf I; Brümmendorf TH; Jost E; Steffen B; Bug G; Einsele H; Görlich D; Sauerland C; Schäfer-Eckart K; Krause SW; Hänel M; Hanoun M; Kaufmann M; Wörmann B; Kramer M; Sockel K; Egger-Heidrich K; Herold T; Ehninger G; Burchert A; Platzbecker U; Berdel WE; Müller-Tidow C; Hiddemann W; Serve H; Stelljes M; Baldus CD; Neubauer A; Schetelig J; Thiede C; Bornhäuser M; Middeke JM; Stölzel F;
    J Hematol Oncol; 2022 Sep; 15(1):126. PubMed ID: 36064577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IDH2 Mutation Analysis in Undifferentiated and Poorly Differentiated Sinonasal Carcinomas for Diagnosis and Clinical Management.
    Riobello C; López-Hernández A; Cabal VN; García-Marín R; Suárez-Fernández L; Sánchez-Fernández P; Vivanco B; Blanco V; López F; Franchi A; Llorente JL; Hermsen MA
    Am J Surg Pathol; 2020 Mar; 44(3):396-405. PubMed ID: 31876581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction.
    Gondim DD; Gener MA; Curless KL; Cohen-Gadol AA; Hattab EM; Cheng L
    Appl Immunohistochem Mol Morphol; 2019; 27(10):722-725. PubMed ID: 30358614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
    Amary MF; Bacsi K; Maggiani F; Damato S; Halai D; Berisha F; Pollock R; O'Donnell P; Grigoriadis A; Diss T; Eskandarpour M; Presneau N; Hogendoorn PC; Futreal A; Tirabosco R; Flanagan AM
    J Pathol; 2011 Jul; 224(3):334-43. PubMed ID: 21598255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.